©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Down-regulation of Tumor Necrosis Factor Receptors by Blockade of Mitochondrial Respiration (*)

(Received for publication, April 28, 1995; and in revised form, June 23, 1995)

José A. Sánchez-Alcázar Inmaculada Hernández María P. De la Torre Inmaculada García Ernesto Santiago María T. Muñoz-Yagüe José A. Solís-Herruzo (§)

From the Centro de Investigación, Servicio de Gastroenterología, Hospital Universitario ``12 de Octubre,'' Universidad Complutense, 28041 Madrid, Spain

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

We have studied the effect of blockade of mitochondrial respiration on the binding of human I-TNFalpha to L929 cell receptors. Specific TNFalpha binding was decreased to about 20-40% of controls by blocking mitochondrial respiration. This effect was dose- and time-related and was observed independently of the level at which the respiration was blocked (respiratory chain, proton backflow, ATPase, anaerobiosis). This blockade had no effect on the half-life of the specific TNFalpha binding, the internalization or degradation of TNFalpha-receptor complexes, or the number of TNFalpha-binding sites. Scatchard analysis of TNFalpha binding data indicated a 2-4-fold decrease in the affinity of these binding sites. These effects did not appear to be related to the protein kinase C activity or to reactive oxygen radicals, since they were not antagonized by pretreatment of cells with oxygen radical scavengers, deferoxamine, or inhibitors of protein kinase C. Decrease in TNFalpha binding capacity correlated significantly with cellular ATP content (r = 0.94; p < 0.01) and with the cytocidal activity of TNFalpha against L929 cells. These findings suggest that blockade of mitochondrial respiration down-regulates the binding of TNFalpha to cells, most likely by changing the affinity of receptors for this cytokine. This down-regulation may increase the resistance of cells to TNFalpha cytotoxicity.


INTRODUCTION

Tumor necrosis factor alpha (TNFalpha) is a polypeptide cytokine with a wide range of biological activities(1, 2, 3, 4) , including tumor cytotoxicity(5) . TNFalpha initiates its biological effects by its binding to high affinity receptors(6) . The expression of these receptors is necessary to determine responsiveness of target cells(7) . It has also shown that some intracellular events, such as protein kinase C activity or intracellular levels of cAMP may regulate the binding of TNFalpha to these specific receptors(8, 9, 10, 11, 12, 13, 14) . Two TNFalpha receptors have been recognized: a type I receptor of 55-60 kDa and a type II receptor of 75-80 kDa. The cytocidal effect of TNFalpha is believed to be transduced by the type I receptor(15) , although the type II receptor may also contribute to this effect(16, 17) . Unlike the species-specific type II receptor, the type I receptor in the murine L929 cell will bind heterologous (i.e. human) TNFalpha (18) and may initiate apoptotic cell death. In this paper, we show that mitochondrial function modulates the binding of TNFalpha to cell receptors, an event that might influence the effects of this cytokine on cell cytotoxicity. Mitochondrial dysfunction has been suggested to be an early event of TNFalpha cytotoxicity in tumor cells (19


EXPERIMENTAL PROCEDURES

Materials

Recombinant human TNFalpha was purchased from Genzyme Co. (Cambridge, MA). RPMI 1640 medium was from Biochrom (Berlin, Germany), and I-Bolton-Hunter-labeled human TNFalpha (specific activity, 48.8 µCi/µg) was from DuPont NEN. SDS, rotenone, thenoyltrifluoroacetone (TTFA), (^1)antimycin A, potassium cyanide (KCN), malonic acid, 2,4-dinitrophenol, oligomycin, actinomycin D, cycloheximide, sodium orthovanadate, okadaic acid, staurosporine, and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) were purchased from Sigma. Fetal calf serum (FCS) was from Sera-lab (Sussex, United Kingdom), and phosphate buffered saline was from SCN Biomedicals, Inc. (Costa Mesa, CA). Plastic cell culture flasks and dishes were from Nunc (Roskilde, Denmark) and Falcon Division of Becton Dickinson Co. (Oxnard, CA).

Methods

L929 cells, a murine fibrosarcoma cell line, were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, glutamine, penicillin (100 units/ml), and streptomycin (0.1 mg/ml) in a humidified incubator in 5% CO(2) in air.

Binding Assays

Binding assays were performed in confluent cultures in 35-mm plastic plates containing approximately 1 times 10^6 L929 cells, as described by Tsujimoto et al.(20) . The effect of inhibitors of mitochondrial respiratory chain on the binding of TNFalpha to specific cell receptors was evaluated by the same assay after incubation of L929 cells with these agents for 1, 2, or 3 h at 37 °C. NADH-dehydrogenase complex (complex I) was inhibited with rotenone; succinate dehydrogenase (complex II) was inhibited with TTFA and malonic acid; b-c(1) complex (complex III) was inhibited with antimycin A; cytochrome oxidase complex (cytochrome a-a(3); complex IV) was inhibited with KCN and NaF; and ATPase was inhibited with oligomycin. As uncoupling agent, 2,4-dinitrophenol was used, and as phosphatase inhibitors, sodium orthovanadate and okadaic acid were employed. Anaerobiosis was induced by incubating cells in a nitrogen atmosphere, after replacing oxygen by nitrogen and sealing culture flasks tightly. All of these assays were carried out in quadruplicate. At the time of the TNF binding studies, no evidence of cytotoxicity was detected. Calculation of the dissociation constant (K(d)) and the number of binding sites was done by Scatchard plot analysis of the binding(21) , as described by Linge and Green(22) , under control conditions and after incubation of cells with either 10 µg/ml antimycin A or 0.24 µM rotenone for 2 h at 37 °C. These assays were performed in duplicate.

Internalization of cell-bound TNFalpha was evaluated by the procedure described by Costlow and Hample (23) and modified by Tsujimoto et al.(20) . Degradation of internalized TNFalpha was measured following the indication of Tsujimoto et al.(20) .

Cytotoxicity

Fifty microliters of solution containing the inhibitory drug were added to L929 cells cultured in 35-mm plates at 1 times 10^6 cells in 2 ml RPMI 1640 medium. At the time indicated, 25 ng/ml human TNFalpha and 1 µg/ml actinomycin D were added to the culture medium. Cytotoxicity was measured using the index of lactate dehydrogenase enzyme leakage from damaged cells and expressed as a percentage of total cellular activity, as described by Decker and Lohmann-Matthes(24) .

Intracellular ATP Concentration

ATP content was measured using a modified bioluminiscence assay as described by Wulff and Döppen(25) . Cellular ATP levels were expressed in nmol/10^6 cells.

Statistical Analysis

All results are expressed as mean ± S.D. unless otherwise mentioned. Student's t test was used to evaluate the difference in means between groups, accepting p < 0.05 as level of significance(26) . Pearson's correlation coefficient was used for correlation analysis between variables that demonstrated statistically significant changes after treatment of cells.


RESULTS

Effect of Blocking the Mitochondrial Respiratory Chain on Specific TNFalpha Binding to Cell Receptors

Complex I of the respiratory chain accepts electrons from NADH and transfers them to ubiquinone (27) (Fig. 1). The blockade of this transfer of electrons through complex I by incubating cells with 0.24 µM and 30 µM rotenone for 1-3 h led to a marked decrease in the binding of TNFalpha to specific type I cell receptors. This effect increased in proportion to the incubation time, there being only 19 ± 7% of the control binding after 3 h of incubation with 30 µM rotenone (Table 1).


Figure 1: Schema of the mitochondrial respiratory chain, showing action sites of inhibitors. DFX, deferoxamine; DNP, 2,4-dinitrophenol; OHbullet, hydroxyl radical; SOD, superoxide dismutase; TTFA, thenoyltrifluoroacetone; UQ, ubiquinone.





Ubiquinone passes these electrons to the b-c(1) complex (complex III), which transfers them to cytochrome c(27) . The function of complex III can be blocked with antimycin A (Fig. 1). Therefore, we incubated L929 cells either with 10 µg/ml or 26 µg/ml antimycin A for 1 to 3 h. Our study showed that the blockade of this complex decreased TNFalpha binding to about 40 and 30%, respectively, of the control after 3 h of incubation (Table 1).

Cytochrome c is involved in carrying electrons from the b-c(1) complex to the cytochrome oxidase complex (cytochrome a-a(3), or complex IV). This complex finally transfers these electrons to oxygen (27) . KCN binds to this complex and thereby blocks the transport of electrons. Treatment of cells with either 250 µM or 500 µM KCN for 3 h reduced TNFalpha binding to 47 and 37%, respectively, of controls (Table 1). Likewise, 5 mM NaF, another inhibitor of cytochrome c oxidase, decreased specific binding of TNFalpha to 18% of the control level after 3 h of incubation (Fig. 2A).


Figure 2: Effect of 2,4-dinitrophenol, NaF, malonic acid, and anaerobiosis on TNFalpha binding to L929 cells. Confluent cultures of L929 cells were incubated with either 2 µM 2,4-dinitrophenol or 5 mM NaF or were incubated in a nitrogenous atmosphere for 3 h at 37 °C (panelA). In panelB, confluent cells were incubated with increasing concentrations of malonic acid for 3 h at 37 °C. After incubation, specific binding was measured as described under ``Experimental Procedures'' and Table 1. Data are expressed as percentage of radioactivity of control cultures and are representative of two independent experiments that were carried out in quadruplicate.



Transport of electrons through the respiratory chain is coupled to the pumping of protons from the mitochondrial matrix to the intermembrane space. ATPase synthesizes ATP when protons flow back from the intermembrane space into the matrix(27) . Oligomycin inhibits ATPase activity, and lipophilic weak acids uncouple electron transport from ATP synthesis. Incubation of L929 cells for 3 h with either 10 µg/ml oligomycin or 2 µM 2,4-dinitrophenol, an uncoupling agent, decreased the binding of TNFalpha to 27 and 57%, respectively, of control values ( Table 1and Fig. 2A).

FADH(2) remains as a part of the succinate dehydrogenase complex (complex II), which passes its electrons directly to ubiquinone (Fig. 1). Addition of TTFA (250 µM) to the cells led to a gradual decrease in TNFalpha binding from 81% after 1 h of incubation to 63 and 29% after 2 and 3 h of incubation, respectively (Table 1). Likewise, incubation of cells with malonic acid, a competitive inhibitor of complex II, induced a dose-related inhibition of the TNFalpha binding (Fig. 2A).

In the absence of oxygen, respiratory enzyme complexes are in their reduced state, being unable to generate ATP. Incubation of L929 cells in anaerobic conditions for 3 h reduced the TNFalpha binding to 45% of the control (Fig. 2A).

Effect of Inhibitors of the Respiratory Chain on Number, Affinity, Internalization, Degradation and Half-life of the TNFalpha Cell Receptors

Scatchard analysis of the binding data showed that the dissociation constant of TNFalpha receptors in L929 cells was 5.7 times 10M and that the average number of specific binding sites was about 3372/cell. These results concurred with those reported by Tsujimoto et al.(20) . Scatchard analysis after treatment of L929 cells for 2 h with either 10 µg/ml antimycin A or 0.24 µM rotenone, two powerful inhibitors of TNFalpha binding, indicated a 2-4-fold decrease in the receptor affinity (rotenone-treated: K(d) = 11.7 times 10M; antimycin A-treated: K(d) = 21.9 times 10M). In rotenone-treated cells, the number of specific binding sites did not differ significantly (3308 binding sites) from those of control cells. However, this number decreased slightly, to 82% of the controls, in cells treated with antimycin A (2752 binding sites) (Fig. 3).


Figure 3: Equilibrium saturation of TNFalpha binding to L929 cells and Scatchard analysis of the binding data. Cultures of 1 times 10^6 L929 cells were incubated with increasing concentrations of human I-TNFalpha in the absence (control) or presence of either 10 µg/ml antimycin A or 0.24 µM rotenone. Specific binding was calculated as described in Fig. 2and under ``Experimental Procedures.'' Scatchard plot analysis of the binding data at 4 °C is shown in the inset. Diagrams are representative of experiments that were carried out twice. The data represent the mean of duplicate samples.



Neither 10 µg/ml antimycin A nor 250 µM KCN, the less effective blocker of TNFalpha binding, modified the rate of internalization of human I-TNFalpha. Intracellular radioactivity resistant to acid elution rose early after incubation of cells at 37 °C, but this rise was followed by a slow decline. No significant differences were seen in the kinetics of intracellular TNFalpha between control cells and cells treated with either antimycin A or KCN (Fig. 4A). Analysis of I radioactivity in the TCA-soluble fraction of culture medium showed a significant increase after 2 h of incubation and continued rising gradually until 6 h (Fig. 4A). The kinetics of this increase were identical in control cells and after blocking the mitochondrial respiratory chain with antimycin A or KCN.


Figure 4: Effect of blockade of mitochondrial respiration on internalization, degradation, and half-life of TNFalpha binding sites. PanelA, human I-TNFalpha was allowed to bind to L929 cells for 2 h at 4 °C. Then cells were washed four times with ice-cold RPMI 1640 medium containing 10% FCS and further incubated at 37 °C in the absence (control) or presence of either 10 µg/ml antimycin A or 250 µM KCN. After the indicated times, cells were washed once with ice-cold phosphate-buffered saline and incubated for 5 min at 4 °C with 2 ml 0.05 M glycine-HCl buffer (pH 3.0) containing 0.15 NaCl. After removal of this buffer, cells were washed twice with RPMI 1640 medium containing 10% FCS and solubilized in 0.1% SDS. I-radioactivity found in the trichloracetic acid-soluble fraction of culture media collected before addition of the glycine buffer and in solubilized cells gave a measure of degradation and internalization, respectively, of TNFalpha-receptor complex. Diagram is representative of two separate experiments. PanelB, L929 cells were incubated with or without 10 µg/ml antimycin A in the presence or absence of 0.1 mM cycloheximide at 37 °C. At the indicated times TNFalpha binding capacity was determined as indicated in Table 1and under ``Experimental Procedures.'' Specific human I-TNFalpha binding is given as percentage of untreated cells (11,300 ± 635 cpm). Data represent the mean of triplicate samples. CHX, cycloheximide.



Blocking protein synthesis with 0.1 mM cycloheximide revealed a half-life of TNFalpha-receptors of about 2 h in control cells. This result is in agreement with those reported by others(11, 14) . Treatment of cells with 10 µg/ml antimycin A did not modify this half-life (Fig. 4B).

To explore the role played by reactive oxygen radicals formed throughout the mitochondrial respiratory chain, we analyzed the effect of scavengers of these radicals and iron chelators on antimycin A-induced inhibition of TNFalpha binding capacity. Treatment of cells with 10 µg/ml antimycin A decreased the specific binding of TNFalpha to 37 ± 7% of control cells (Fig. 5). However, the addition of 10 µg/ml superoxide dismutase, an enzyme that removes superoxide anion from the cells, as well as 100 mM mannitol, a scavenger of hydroxyl radicals, or 100 µM deferoxamine, a specific iron chelator, did not antagonize this effect of antimycin A (Fig. 5). We also studied the effect of the protein kinase C inhibitors H-7 and staurosporine on the decreased binding of TNFalpha to L929 cells induced by antimycin A (10 µg/ml). As Fig. 5shows, neither H-7 (50 µM) nor staurosporine (0.5 nM) had any significant effect on the specific binding of TNFalpha to these cells, and neither of them antagonized the antimycin A-induced reduction of TNFalpha binding activity. Likewise, the addition of orthovanadate (1 µg/ml) or okadaic acid (20 ng/ml), two phosphatase inhibitors, did not reverse the effect of antimycin A on TNFalpha binding to the cells (data not shown).


Figure 5: Effect of oxygen radical scavengers and protein kinase C inhibitors on antimycin A-induced reduction of TNFalpha binding capacity to L929 cells. L929 cells were pretreated for 3 h with 10 µg/ml antimycin A (A) in the presence or absence of one of the following agents: 0.5 nM staurosporine (St), 50 µM H-7 (H7), 10 µg/ml superoxide dismutase (SD), 100 µM deferoxamine (DF), or 100 mM mannitol (M). Afterward, specific TNFalpha binding was quantified as described in Fig. 2and ``Experimental Procedures.'' Specific binding is expressed as percentage of radioactivity of untreated cells (C) cultured in RPMI 1640 medium without antimycin A but otherwise processed in the same way (15,187 ± 695 cpm). Values are means ± S.D. of triplicate samples.



Effect of Blockade of the Mitochondrial Respiratory Chain on Intracellular ATP Levels

As expected, incubation of L929 cells for 2 h with any inhibitor of cellular respiration resulted in a significant decrease in the intracellular ATP content (Fig. 6A). These levels correlated significantly with the binding of TNFalpha to cells treated for 2 h with the inhibitor (r = 0.94; p < 0.01) (Fig. 6B).


Figure 6: Effect of blockade of the mitochondrial respiration on intracellular content of ATP. PanelA, L929 cells were incubated for 2 h at 37 °C with a series of inhibitors of mitochondrial respiration and then solubilized. The ATP content was determined as described under ``Experimental Procedures.'' The data represent values from triplicate samples and are expressed as mean ± S.D. C, controls; R, 0.24 µM rotenone; A1, 10 µg/ml antimycin A; A2, 26 µg/ml antimycin A; CN, 250 µM potassium cyanide; O, 10 µg/ml oligomycin; T, 250 µM TTFA. PanelB, diagram represents correlation between intracellular ATP content and specific TNFalpha binding in cells pretreated with a number of inhibitors of mitochondrial respiration. Data represent the mean of triplicate samples.



Effect of Inhibition of the Mitochondrial Respiratory Chain on TNFalpha-induced Cytotoxicity

The effect of the pretreatment of cells for 2 h with various inhibitors of the respiratory chain on TNFalpha-induced cytotoxicity is shown in Fig. 7A. L929 cells are sensitive to the cytocidal activity of 25 ng/ml human TNFalpha in the presence of 1 µg/ml actinomycin D. Cells treated with any inhibitor of the respiratory chain become more resistant to this effect of TNFalpha. In most cases, resistance to cytolysis persisted 24 h after application of the cytokine. Blockade of complex I (0.24 µM rotenone) reduced cytocidal activity of TNFalpha to 20% of controls after 9 h of incubation with TNFalpha. Likewise, inhibition of the b-c(1) complex (10 µg/ml antimycin A), blockade of ATPase (10 µg/ml oligomycin) or treatment of cells with 2 µM 2,4-dinitrophenol decreased cytotoxicity of TNFalpha to 34, 25, and 11%, respectively, of controls. In contrast, blockade of cytochrome c oxidase with 250 µM KCN resulted in a moderate reduction in the cell death after 9 h of incubation with TNFalpha to 68% of control values. Treatment of cells with 25 ng/ml TNFalpha and 1 µg/ml actinomycin D under aerobic conditions for 12 h induced the cytolysis of about 50% of the cells. However, only 10% of the cells died in the absence of oxygen. Anaerobiosis 4 h after the addition of TNFalpha did not significantly protect cells from TNFalpha (Table 2). Likewise, resistance to cytolysis decreased when the respiratory chain was inhibited by other agents 1-4 h after the addition of TNFalpha.


Figure 7: Resistance of L929 cells to TNFalpha cytotoxicity induced by inhibition of mitochondrial respiration. PanelA, L929 cells were pretreated for 2 h with 250 µM potassium cyanide, 10 µg/ml oligomycin, 0.24 µM rotenone, 10 µg/ml antimycin A, 2 µM 2,5-dinitrophenol (DNP), or in anaerobiosis and incubated for the indicated time periods with 25 ng/ml human TNFalpha and 1 µg/ml actinomycin D. Cytotoxicity was assessed as described under ``Experimental Procedures.'' Data were collected from triplicate samples. Values are expressed as percent of TNFalpha cytotoxicity on control cells. PanelB, diagram represents correlation between TNFalpha cytotoxicity and specific TNFalpha binding to cells treated with 10 µg/ml antimycin A or 0.24 µM rotenone. Cells were pretreated with these inhibitors for 1, 2, or 3 h. After these pretreatment times, TNF binding and TNF cytotoxicity were measured as indicated in Table 1and Table 2.





Cytotoxicity of TNFalpha on L929 cells pretreated with rotenone or antimycin A correlated closely with the binding of TNFalpha to these cells (Fig. 7B).


DISCUSSION

In this study, we show that treatment of L929 cells with a number of inhibitors of cellular respiration resulted in a significant decrease in the binding of human TNFalpha to cell surface receptors. Although there were some differences in the degree of this inhibition depending on the drug used for blocking the transport of electrons throughout the respiratory chain, this effect was observed independently of the level at which the inhibition was induced. Down-regulation of TNFalpha binding by blocking cellular respiration was intensified in proportion to the incubation time and to the concentration of inhibitor in the culture medium. After 3 h of inhibition, the binding of human I-TNFalpha to cell receptors was only 18-47% of the control. This effect on TNFalpha binding had biological implications, since it was followed by a decrease in the cytocidal activity of TNFalpha in L929 cells, and both effects, TNFalpha binding and TNFalpha cytotoxicity, were closely correlated. Thus, the interpretation of changes in TNFalpha-mediated cytotoxicity induced by pretreatment of cells with inhibitors of the mitochondrial respiratory chain as well as by any other factor demands that this effect on TNFalpha binding be taken into account.

Several factors have been identified as modulators of TNFalpha-receptor function. These factors include protein kinase C and interleukin-1 (8, 9, 10, 11, 12) , which are involved in the down-regulation of TNFalpha binding. In contrast, cAMP, protein kinase A (13, 14) and interferon- up-regulate this binding(14, 28, 29) . Now we demonstrate that there is a close relationship between cellular respiration and the binding of TNFalpha to its specific type I receptors.

The mechanisms by which the blockade of the mitochondrial respiratory chain led to a down-regulation of the TNFalpha binding capacity of L929 cells are not known. This effect cannot be attributed to a reduced cell viability as a result of these treatments, since no cell death was detected at the time these experiments were done. On the contrary, these treatments protect the cells from TNF-induced cytotoxicity. This effect could be also due to changes in the number of receptors or in their affinity for the ligand but might also reflect modifications in the kinetics of receptor-ligand complex internalization and degradation or an increase in the shedding of TNFalpha receptor into the culture medium.

The binding of TNFalpha to specific cell receptors is usually followed by internalization of the receptor-TNFalpha complex into the cell and by degradation of TNFalpha by lysosomal hydrolases(30) . However, our study detected no significant difference in the kinetics of internalization or degradation of human I-TNFalpha between untreated cells and cells treated with either antimycin A or KCN (Fig. 4). Moreover, determination of the half-life of TNFalpha binding sites showed that it is not affected by blocking of the respiratory chain, suggesting that it is unlikely that increased degradation or shedding of these receptors can account for the down-regulation of the TNFalpha binding capacity of cells. On the other hand, Scatchard analysis of antimycin A or rotenone-treated L929 cells indicated that the number of TNFalpha receptors did not change significantly, ruling out the possibility that a change in TNFalpha-receptor synthesis may account for this down-regulation. Likewise, this result led to doubts about an enhanced shedding of TNFalpha receptors as the cause of the reduced binding of TNFalpha to these cells. Our data indicate that this effect is better explained by a decrease in receptor affinity. Scatchard analysis showed that the affinity of TNFalpha binding sites was markedly decreased in cells treated with either antimycin A or rotenone. Thus, while TNFalpha binding sites had a dissociation constant of 5.7 times 10M in control cells, this constant increased between 2- and 4-fold in cells treated with rotenone (K(d) = 11.7 times 10M) or antimycin A (K(d) = 21.9 times 10M).

Blockade of the respiratory chain has a number of consequences for cell metabolism and function. Mitochondria are the major source of reactive oxygen species(31, 32, 33) , and, under certain conditions, including mitochondrial inhibition and TNFalpha treatment, generation of reactive oxygen radicals increases severalfold(19, 34, 35, 36, 37, 38, 39, 40, 41, 42) . Our results do not support the involvement of these radicals as mediators for this relationship between mitochondrial respiration and TNFalpha binding to the cells. Neither superoxide dismutase nor mannitol prevented the inhibitory effect of antimycin A on the TNFalpha binding capacity of cells (Fig. 6). Conversion of superoxide anion and hydrogen peroxide to hydroxyl radical can be catalyzed by iron ions. However, chelation of these ions by deferoxamine had no effect on TNFalpha binding either. Moreover, anaerobiosis, a condition under which no reactive oxygen radicals are generated, significantly decreased TNF binding to L929 cells (Fig. 2A).

It has been demonstrated that TNFalpha binding to the cell receptors can be significantly decreased by activation of protein kinase C(8, 9, 10, 11, 12, 43) . The mechanism of this effect is unclear(8, 9, 11, 14) . However, it has been shown that activation of protein kinase C enhances shedding of TNFalpha receptors into the medium(43, 44, 45) . It has been suggested that the decrease in TNFalpha binding sites caused by phorbol myristate acetate is most likely mediated through enhanced phosphorylation and activation of a cellular protease, which cleaves the TNFalpha-receptors (43) . Protein kinase C has been shown to have similar down-regulating effects on other cell receptors(46, 47, 48) , and Dowing et al.(49) reported that phorbol myristate acetate increased shedding of CSF-1 receptors through protein kinase C-mediated activation of a protease. The results of our study appear to indicate that the effect of blockade of the mitochondrial respiratory chain on TNFalpha binding activity is not likely to be mediated by a protein kinase C-phosphorylated protein. Neither the inhibition of this enzyme with H-7 or staurosporine nor the blockade of cellular phosphatase with orthovanadate or okadaic acid antagonized the effect of antimycin A on TNFalpha binding activity (Fig. 5). Moreover, blocking the mitochondrial transfer of electrons decreased TNFalpha receptor affinity markedly, with no significant effect on the number of these receptors (Fig. 3). As we have previously commented, receptor shedding also seems unlikely since the half-life of TNFalpha-receptors was not reduced.

In this study, we found that the binding capacity of L929 cells for TNFalpha was significantly correlated with the intracellular concentration of ATP. This finding suggests that the cellular ATP content may have a direct or indirect modulatory role in the TNFalpha binding activity of TNFalpha receptors. As far as we are aware, no data regarding cellular ATP levels and TNFalpha receptors have been published so far. A series of studies have found some relationships between other hormone receptors and ATP content in cells(50, 51, 52, 53, 54, 55) . However, results from these studies are heterogeneous and frequently contradictory and thus fail to indicate a possible common mechanism of action. It is conceivable that the binding of TNFalpha to specific cell receptors is an energy-consuming process. However, further studies are required to explain this relationship.

This down-regulation could be simply a side effect of mitochondrial dysfunction, secondary to the loss of cellular energy and, therefore, lacking in teleologic meaning. However, we could speculate that this mechanism might protect cells from being killed by TNFalpha. It has been shown that TNFalpha treatment leads to a dose-dependent inhibition of mitochondrial transport of electrons and to the formation of reactive oxygen species(19, 37, 38, 39, 40, 42) . Based on abundant evidence, it has been suggested that these reactive metabolites play a major role in the cytotoxicity induced by TNFalpha(19, 37, 38, 42, 56, 57) . Thus, down-regulation of TNFalpha binding by blockade of the mitochondrial respiratory chain might reduce the biological effects of TNFalpha and, consequently, could diminish oxidative stress, hydroxyl radical generation, and cell death. Holtmann and Wallach(8) , Wallach et al.(58) and Hahn et al.(59) showed that cells pretreated with TNFalpha for 1-12 h became more resistant to the cytocidal effect of TNFalpha, and Aggarwal et al.(28) demonstrated that TNFalpha and TNFbeta inhibit the binding of TNFalpha to the cells. Other mechanisms of self-protection have been shown to be induced by TNFalpha. This is the case for manganous superoxide dismutase, a mitochondrial enzyme involved in the scavenging of superoxide radicals. Wong et al.(56, 57) and Hirose et al.(60) demonstrated that treatment of cells with TNFalpha induces the expression of mRNA for this enzyme, and these investigators proposed manganese superoxide dismutase as one of the protective proteins whose synthesis is induced by TNFalpha.

We conclude that blockade of the mitochondrial respiratory chain down-regulates the binding of TNFalpha to L929 cells, most likely by decreasing the affinity of TNFalpha receptors for this cytokine. The mechanism of this down-regulation is not known, but it appears to be closely related to intracellular ATP levels. This down-regulation may increase the resistance of cells to TNFalpha cytotoxicity.


FOOTNOTES

*
This study was supported in part by ``Fondo de Investigaciones Sanitarias'' Grants 90/145 and 90/148, DGICYT Grant PB-92/316, and ``Fundación Salud 2000,'' Spain. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Servicio de Aparato Digestivo, Hospital ``12 de Octubre,'' Carretera Andalucía 4.5, 28041 Madrid, Spain. Fax: 34-1-390-8358.

(^1)
The abbreviations used are: TTFA, thenoyltrifluoroacetone; KCN, potassium cyanide; FCS, fetal calf serum; H-7, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride.


ACKNOWLEDGEMENTS

We thank Martha E. Messman for assistance in preparing this manuscript.


REFERENCES

  1. Beutler, B., and Cerami, A. (1987) N. Engl. J. Med. 316,379-385 [Medline] [Order article via Infotrieve]
  2. Perlmutter, D. H, Dinarello, C. A., Punsal, P. I., and Colten, H. R. (1986) J. Clin. Invest. 78,1349-1354 [Medline] [Order article via Infotrieve]
  3. Tracey, K. J., Vlassara, H., and Cerami, A. (1989) Lancet 20,1122-1126
  4. Beutler, B., and Cerami, A. (1988) Annu. Rev. Biochem. 57,505-518 [CrossRef][Medline] [Order article via Infotrieve]
  5. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. (1957) Proc. Natl. Acad. Sci. U. S. A. 72,3666-3670
  6. Kaplan, J. (1981) Science 212,14-20 [Medline] [Order article via Infotrieve]
  7. Camussi, G., Albano, E., Tetta, C., and Bussolino, F. (1991) Eur. J. Biol. Biochim. 202,3-14
  8. Holtmann, H., and Wallach, D. (1987) J. Immunol. 139,1161-1167 [Abstract/Free Full Text]
  9. Johnson, S. E., and Baglioni, C. (1988) J. Biol. Chem. 263,5686-5692 [Abstract/Free Full Text]
  10. Aggarwal, B. B., and Eessalu, T. E. (1987) J. Biol. Chem. 262,16450-16455 [Abstract/Free Full Text]
  11. Unglaub, R., Maxeiner, B., Thoma, B., Pfizenmaier, K., and Scheurich, P. (1987) J. Exp. Med. 166,1788-1797 [Abstract]
  12. Scheurich, P., Unglaub, R., Maxeiner, B., Thoma, B., Zugmaier, G., and Pfizenmaier, K. (1989) Bichem. Biophys. Res. Commun. 141,855-860
  13. Hohmann, H. P., Brockhaus, M., Baeuerle, P. A., Remy, R., Kolbeck, R., and van Loon, A. P. G. M. (1990) J. Biol. Chem. 265,22409-22417 [Abstract/Free Full Text]
  14. Scheurich, P., Köbrich, G., and Pfizenmaier, K. (1989) J. Exp. Med. 170,947-958 [Abstract]
  15. Tartaglia, L. A., and Goeddel, D. V. (1992) J. Biol. Chem. 267,4304-4307 [Abstract/Free Full Text]
  16. Heller, R. A., Song, K., Fan, N., and Chang, D. J. (1992) Cell 70,47-56 [Medline] [Order article via Infotrieve]
  17. Bidga, J., Beletstry, I., Brakebush, C., Varfolomeer, Y., Engelmann, H., Bidga, J., Holtmann, H., and Wallach, D. (1994) J. Exp. Med. 180,445-460 [Abstract]
  18. Knauer, M. F., Longmuir, K. J., Yamamoto, R. S., Fitzgerald, T. P., and Granger, G. A. (1990) J. Cell. Physiol. 142,469-479 [Medline] [Order article via Infotrieve]
  19. Lancaster, J. R., Jr., Laster, S. M., and Gooding, L. R. (1989) FEBS Lett. 248,169-174 [CrossRef][Medline] [Order article via Infotrieve]
  20. Tsujimoto, M., Yip, Y. K., and Vilcek, J. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,7626-7630 [Abstract]
  21. Scatchard, G. (1949) Ann. N. Y. Acad. Sci. 51,660-672
  22. Linge, C., and Green, M. R. (1993) in Growth Factor: A Practical Approach (McKay, I., Leigh, I., eds), pp. 201-236, Oxford University Press, Oxford
  23. Costlow, M. E., and Hample, A. (1982) J. Biol. Chem. 257,9330-9334 [Abstract/Free Full Text]
  24. Decker, T., and Lohmann-Matthes, M. L. (1988) J. Immunol. Methods 15,61-69
  25. Wulff, K., and D ö ppen, W. (1985) in Methods of Enzymatic Analysis , 3rd Ed., Vol. 7. (Bergmeyer, H. V., ed) pp. 357-364, Verlag-Chimie, Weiheim
  26. Colton, T. (1979) Estadística en Medicina, Salvat Editores, S. A. Barcelona
  27. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K., and Watson, J. D. (1989) Molecular Biology of the Cell , 2nd Ed., pp. 342-366, Garland Publications, Inc., New York
  28. Aggarwal, B. B., Eessalu, T. E., and Hass, P. E. (1985) Nature 318,665-667 [Medline] [Order article via Infotrieve]
  29. Tsujimoto, M., Yip, Y. K., and Vilcek, J. (1986) J. Immunol. 136,2441-2444 [Abstract/Free Full Text]
  30. Goldstein, J. L., Anderson, R. G. W., and Brown, M. S. (1979) Nature 279,679-685 [Medline] [Order article via Infotrieve]
  31. Boveris, A., and Chance, B. (1973) Biochem. J. 134,707-716 [Medline] [Order article via Infotrieve]
  32. Boveris, A. (1977) in Tissue Hyporexia and Ischemia (Reivich, M., Coburn, R., Lahiri, S., and Chance, B., eds) pp. 67-82, Plenum Press, New York
  33. Loschen, G., Azzi, A., Richter, C., and Flohé, L. (1974) FEBS Lett. 42,68-72 [CrossRef][Medline] [Order article via Infotrieve]
  34. Boveris, A., Cadenas, E., and Stoppani, A. O. M. (1976) Biochem. J. 156,435-444 [Medline] [Order article via Infotrieve]
  35. Takeshige, K., and Minakami, S. (1979) Biochem. J. 180,129-135 [Medline] [Order article via Infotrieve]
  36. Konstantinov, A. A., Peskin, A. V., Popova, E. Y., Khomutov, G. B., and Ruuge, E. K. (1987) Biochim. Biophys. Acta. 894,1-10 [Medline] [Order article via Infotrieve]
  37. Stadler, J., Bentz, B. G., Harbrecht, B. G., Di Silvio, M., Curran, R. D., Billiar, T. R., Hoffman, R. A., and Simmons, R. L. (1992) Ann. Surg. 216,539-546 [Medline] [Order article via Infotrieve]
  38. Higuchi, M., Shirotani, K., Higashi, N., Toyoshima, S., and Osawa, T. (1992) J. Immunol. 12,41-49
  39. Hennet, T., Richter, C., and Peterhans, E. (1993) Biochem. J. 289,587-592 [Medline] [Order article via Infotrieve]
  40. Adamson, G. M., and Billing, R. E. (1992) Arch. Biochem. Biophys. 294,223-229 [Medline] [Order article via Infotrieve]
  41. Yamauchi, N., Kuriyama, H., Watanabe, N., Neda, H., Maeda, M., and Niitsu, Y. (1989) Cancer Res. 49,1671-1675 [Abstract]
  42. Schulze-Osthoff, K., Bakker, A. C., Vanhaesebroeck, B., Bayaert, R., Jacob, W. A., and Fiers, W. (1992) J. Biol. Chem. 267,5317-5323 [Abstract/Free Full Text]
  43. Brakebush, C., Nophar, Y., Kemper, O., Engelmann, H., and Wallach, D. (1992) EMBO J. 11,943-950 [Abstract]
  44. Aggarwal, B. B., Totpal, K., Pocsik, E., Graff, K., Liao, W., and Higuchi, M. (1993) in Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance (Fiers, W., and Buurman, W. A., eds) pp. 76-80, Karger, Basel
  45. Kohno, T., Brever, M. T., Baker, S. L., Schwartz, P. E., King, M. N., Hale, K. K., Squires, C. H., and Vannice, J. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,8331-8335 [Abstract]
  46. Takayama, S., White, M. F., Lauris, V., and Kahn, R. C. (1984) Proc. Natl. Acad. Sci. U. S. A. 81,7797-7801 [Abstract]
  47. Davis, R. J., and Czech, M. P. (1984) J. Biol. Chem. 259,8545-8549 [Abstract/Free Full Text]
  48. Leeb-Lundberg, L. M., Cotecchia, S., Lomasney, J. W., DeBernadis, J. F., Lefkowitz, R. J., and Caron, M. G. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,5651-5655 [Abstract]
  49. Downing, J. R., Roussel, M. F., and Sherr, C. J. (1989) Mol. Cell. Biol. 9,2890-2896 [Medline] [Order article via Infotrieve]
  50. Hertel, C., Coulter, S. J., and Perkins, J. P. (1986) Mol. Pharmacol. 44,364-370 [Abstract]
  51. Liao, J. F., and Perkins, J. P. (1993) Mol. Pharmacol. 44,364-370 [Abstract]
  52. Burgers, J. A., and Akkerman, J.-W. N. (1993) Biochem. J. 291,157-161 [Medline] [Order article via Infotrieve]
  53. Sibley, D. R., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1987) Cell 48,913-922 [Medline] [Order article via Infotrieve]
  54. Dohlman, H. G., Caron, M. G., and Lefkowitz, R. J. (1987) Biochemistry 26,2657-2664 [Medline] [Order article via Infotrieve]
  55. Svec, F. (1985) Biochim. Biophys. Acta 847,147-154 [Medline] [Order article via Infotrieve]
  56. Wong, G. H. W., Elwell, J. H., Oberley, L. W., and Goeddel, D. V. (1989) Cell 58,923-931 [Medline] [Order article via Infotrieve]
  57. Wong, G. H. W., and Goeddel, D. W. (1988) Science 242,941-944 [Medline] [Order article via Infotrieve]
  58. Wallach, D. (1984) J. Immunol. 132,2464-2469 [Abstract/Free Full Text]
  59. Hahn, T., Toker, L., Budilovsky, S., Aderka, D., Eshhar, Z., and Wallach, D. (1985) Proc. Natl. Acad. Sci. U. S. A. 82,3814-3818 [Abstract]
  60. Hirose, K., Longo, D. L., Oppenheim, J. J., and Matsushima, K. (1993) FASEB J. 7,361-368 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.